Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Case Report of CCDC149-ALK Fusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association - 1 Dec 2022

Lee Hannah, Krishnan Vimal, Wirth Lori J, Nucera Carmelo, Venturina Mariza, Sadow Peter M, Mita Alain, Sacks Wendy

Abstract excerpt

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, usually with an indolent course. ALK fusions are rare in PTC but may give rise to a more aggressive behavior. We report a novel ALK fusion, CCDC149-ALK, not previously described in PTC, detected by next-generation sequencing in a 30-year-old woman with progressive widely metastatic radioiodine-refractory (RAIR) disease to lung, muscle,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine Radioisotopes

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36150036
DOI: 10.1089/thy.2022.0389
PMCID: PMC9918347

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Case Report of CCDC149-ALK Fusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid Carcinoma.PMID 36150036Read ↗

Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.Semantic proximity Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

Descriptive Analysis of Common Fusion Mutations in Papillary Thyroid Carcinoma in Hungary.Semantic proximity Read ↗

Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis.Semantic proximity Read ↗

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.Semantic proximity Read ↗

Targeting EML4-ALK gene fusion variant 3 in thyroid cancerSemantic proximity Read ↗

Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid CarcinomasSemantic proximity Read ↗

Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.Semantic proximity Read ↗

A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma.Semantic proximity Read ↗

Selpercatinib in the treatment of thyroid cancer.Semantic proximity Read ↗

Molecular and Proteomic Profiles of Radioiodine Refractory Papillary Thyroid CancerSemantic proximity Read ↗

ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult populationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.